Sex bias in disease has been widely recognized for decades. Globally, men are at a greater risk of being diagnosed with and dying from cancer than women. In contrast, women experience greater chemotherapy and immunotherapy-associated adverse events (IRAE), the latter often the result of a hyperactivated immune system. In cancer, tumors escape immune detection and elimination through a variety of mechanisms. We use prostate cancer as a model to examine how androgen-dependent tumors undergo immune evasion by utilizing the hormone milieu of the tumor and the host. Notably, we have demonstrated a role for androgen receptor signaling in suppressing CD8 T cell responsiveness to immunotherapy in a T cell intrinsic manner. Furthermore, we also have demonstrated a novel mechanism of androgen receptor-mediated MHCI suppression on tumor cells. Efforts in the lab continue to reveal mechanisms by which hormones can promote immune escape in and beyond prostate cancer.